Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03697967
Other study ID # 2019-1594
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date November 1, 2021

Study information

Verified date April 2022
Source Maisonneuve-Rosemont Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is conducted to evaluate if the prone position of the newborn on the chest of his mother at birth before delayed cord clamping leads to better hematocrit and hemoglobin at 24-48 hours of life compared to supine position.


Description:

At 30 hours of life, laboratory personnel drew a capillary sample from the infant's heel for hemoglobin, hematocrit, and total serum bilirubin at the same time as the newborn metabolic screening sample. There is no added heelstick to routine care, as current standard in our institution requires the bilirubin to be drawn at 30 hours of life. During universal screening for congenital cardiac defects (30 hours of life), a value of cerebral saturation (CrSO2) is measured using NIRS with INVOS (In Vivo Optical Spectroscopy, INVOS System, Covidien, Dublin, Ireland, Somanetics). Sensors are placed over the forehead and the newborn is in supine position.


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date November 1, 2021
Est. primary completion date November 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 2 Minutes
Eligibility Inclusion Criteria: Newborn = 36 weeks gestational age and Born vaginally and Well appearing Exclusion Criteria: Out born infant, Infant born by caesarian section, Preterm born less than 36 weeks GA, Infant with intra uterine growth restriction (IUGR: less than 10th percentile) Asphyxiated infant Infant needing immediate resuscitation, Newborn with malformation (gastroschisis, omphalocele, anal atresia, severe head skin injury, congenital cardiac disease Newborn with mother with preeclampsia or gestational hypertension or diabetes on insuline or hemolytic disease or on chemotherapy or on cortisone.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
supine or prone position
Before delivery, a sealed enveloppe is opened by the physician or nurse present at delivery. Immediately at birth the team in charge of delivery place the newborn in skin to skin contact on the mother's chest where he is dried. Umbilical cord clamping is delayed in both intervention arms to 1 minute after birth. The newborn is placed in the prone or in the supine position depending on allocation. The nurse in charge of the newborn uses a stopwatch to check the time at which clamping was accomplished. All subsequent nursery care are conducted according to hospital protocol.

Locations

Country Name City State
Canada Brahim Bensouda Montréal-Est Quebec

Sponsors (1)

Lead Sponsor Collaborator
Maisonneuve-Rosemont Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hemoglobin and hematocrit Hemoglobin value 24-48 hours
Secondary Cerebral saturation by near infrared spectroscopy (NIRS) Cerebral saturation by near infrared spectroscopy 24-48 H of life
Secondary Bilirubin Bilirubin value 24-48 hours
See also
  Status Clinical Trial Phase
Completed NCT03604887 - Umbilical Cord Length Index for Prediction of Cord Abnormalities Before Delivery